COLUMBUS OS data favor encorafenib–binimetinib for advanced BRAF-mutated melanoma

Source: Medwire News, June 2018

medwireNews: An updated analysis of the phase III COLUMBUS trial adds to the evidence supporting a combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in patients with advanced BRAF V600-mutant melanoma.

Presenting the findings at the ASCO Annual Meeting 2018, Reinhard Dummer (University Hospital Zürich, Switzerland) explained that the combination previously showed a “clear advantage” with regard to progression-free survival relative to vemurafenib.

Menu